Newsroom

  • FarmaMondo Group receives GMP license from the Danish Medicines Agency

    FarmaMondo Nordics Aps, a fully owned subsidiary of FarmaMondo SA, has received a GMP license from the Danish Medicines Agency. [...]

    Published On: October 15, 2018
  • FarmaMondo Group to manage access to Asparaginase (Spectrila® by Medac Pharma) for patients with acute lymphoblastic leukemia

    FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program [...]

    Published On: August 20, 2018
  • FarmaMondo To Attend Upcoming Pharmagora Paris – 2018

    FarmaMondo Team is pleased to inform you that  is attending Pharmagora Paris 2018. PharmagoraPlus has been the single largest conference and [...]

    Published On: March 21, 2018
  • FarmaMondo Group appointed by Amomed Pharma to exclusively Manage Access for Argipressin (Empressin®)

    FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute [...]

    Published On: March 15, 2018
  • FarmaMondo To Attend Upcoming Arab Health – 2018

    FarmaMondo Team is pleased to inform you that also for 2018 is attending Arab Health in Dubai. Arab Health is [...]

    Published On: December 17, 2017
  • FarmaMondo Group to manage access to Qarziba® (Dinutuximab Beta) by EUSA Pharma for patients with High Risk Neuroblastoma

    FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by EUSA Pharma to exclusively distribute [...]

    Published On: October 17, 2017
  • FarmaMondo Group appointed by Ideogen Pharma to Manage Access for Carmustine (Bicnu®)

    FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Ideogen Pharma to exclusively distribute [...]

    Published On: September 7, 2016
  • FarmaMondo Group and AOP signs exclusive partnership for Russia

    Farmamondo and AOP Orphan signs an exclusive registration, marketing and distribution agreement for AOP’s novel therapy Tetrabenazine indicated for Huntington [...]

    Published On: January 20, 2016